BioXcel Therapeutics (NASDAQ:BTAI) has initiated an expanded access program at Massachusetts General Hospital (MGH) to provide its investigational drug, BXCL501, a sublingual thin-film formulation of dexmedetomidine (Dex), to critically ill patients diagnosed with COVID-19 in ICU that may require calming or arousable sedation.
Expanded access, also known as compassionate use, provides an opportunity for patients to receive an investigational treatment prior to regulatory approval when there are no comparable or satisfactory therapeutic alternatives available.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.